1Cell.Ai at ASCO 2025: Explore Our Latest Research
We’re excited to share 19 new posters and abstracts at the 2025 ASCO Annual Meeting. Our latest findings highlight the power of single-cell, live-cell, and ctDNA analysis across a range of cancers.
Read the abstracts:
1. Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. (Read abstract)
2. Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow up patients across cancer types. (Read abstract)
3. PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. (Read abstract)
4. Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. (Read abstract)
5. ctDNA-based clinicogenomic analysis of advanced head and neck cancer patients treated with immune checkpoint inhibitors. (Read abstract)
6. Effect of cell proliferation pathway on accessibility to targeted therapeutics in the spectrum of co-occurring prognostic cellular pathways in pan-cancers. (Read abstract)
7. Mutational spectrum of cell proliferation genes as early predictive markers for aggressive disease in endometrial cancers. (Read abstract)
8. Using live true single-circulating tumor cell comprehensive genomics to show clonal evolution and tumor heterogeneity in pancreatic cancer management. (Read abstract)
9. ctDNA beyond blood: Harnessing pleural effusion circulating tumor DNA for precision lung cancer diagnostics. (Read abstract)
10. Insights into disease progression in endometrial cancers: The role of cell proliferation pathway mutations following adjuvant therapy. (Read abstract)
11. Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. (Read abstract)
12. Effect of co-occurring TP53 and intracellular proliferation pathway mutations on disease recurrence and survival benefits in head and neck cancers. (Read abstract)
13. Comparative of PD-L1 expression on live single circulating tumor cells with PD-L1 in tumor tissue assessed by immunohistochemistry in advanced NSCLC patients. (Read abstract)
14. The non-canonical role of homologous recombination deficiency in the development of immune-cold tumor microenvironment. (Read abstract)
15. Cellular proliferation and tumor suppression pathways as potential targets in clinically aggressive sarcomas. (Read abstract)
16. Assessment of plasma ctDNA mutational profile and heterogeneity in renal cell carcinoma patients. (Read abstract)
17. Association of co-occurring KRAS and gain of function TP53 mutations with aggressive metastasis through comprehensive genomic profiling of pancreatic ductal adenocarcinoma. (Read abstract)
18. Cerebrospinal fluid derived ctDNA and CTC based molecular analysis highlighting the sampling proximity for clinical significance. (Read abstract)
19. EGFR missense mutations to predict skeletal metastasis in lung cancer patients. (Read abstract)
